Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Jun;55(6):653–656. doi: 10.1038/bjc.1987.133

Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.

K R Huber, E P Mayer, D F Mitchell, J Roberts
PMCID: PMC2002038  PMID: 3620309

Full text

PDF
653

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoki T., Sebolt J., Weber G. In vivo inactivation by acivicin of carbamoyl-phosphate synthetase II in rat hepatoma. Biochem Pharmacol. 1982 Mar 15;31(6):927–932. doi: 10.1016/0006-2952(82)90322-7. [DOI] [PubMed] [Google Scholar]
  2. Holcenberg J. S. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase. Cancer Treat Rep. 1979 Jun;63(6):1109–1114. [PubMed] [Google Scholar]
  3. Houchens D. P., Ovejera A. A., Sheridan M. A., Johnson R. K., Bogden A. E., Neil G. L. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep. 1979 Mar;63(3):473–476. [PubMed] [Google Scholar]
  4. Jayaram H. N., Cooney D. A., Ryan J. A., Neil G., Dion R. L., Bono V. H. L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep. 1975 May-Jun;59(3):481–491. [PubMed] [Google Scholar]
  5. LEVENBERG B., MELNICK I., BUCHANAN J. M. Biosynthesis of the purines. XV. The effect of aza-L-serine and 6-diazo-5-oxo-L-norleucine on inosinic acid biosynthesis de novo. J Biol Chem. 1957 Mar;225(1):163–176. [PubMed] [Google Scholar]
  6. Lui M. S., Kizaki H., Weber G. Biochemical pharmacology of acivicin in rat hepatoma cells. Biochem Pharmacol. 1982 Nov 1;31(21):3469–3473. doi: 10.1016/0006-2952(82)90628-1. [DOI] [PubMed] [Google Scholar]
  7. Nichols W. W., Murphy D. G., Cristofalo V. J., Toji L. H., Greene A. E., Dwight S. A. Characterization of a new human diploid cell strain, IMR-90. Science. 1977 Apr 1;196(4285):60–63. doi: 10.1126/science.841339. [DOI] [PubMed] [Google Scholar]
  8. Ovejera A. A., Houchens D. P., Catane R., Sheridan M. A., Muggia F. M. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res. 1979 Aug;39(8):3220–3224. [PubMed] [Google Scholar]
  9. Roberts J. Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7Z. J Biol Chem. 1976 Apr 10;251(7):2119–2123. [PubMed] [Google Scholar]
  10. Roberts J., Schmid F. A., Rosenfeld H. J. Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, L-tryptophan, and L-histidine. Cancer Treat Rep. 1979 Jun;63(6):1045–1054. [PubMed] [Google Scholar]
  11. Rosenfeld H., Roberts J. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase. Cancer Res. 1981 Apr;41(4):1324–1328. [PubMed] [Google Scholar]
  12. Schmid F. A., Roberts J. Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases. Cancer Chemother Rep. 1974 Nov-Dec;58(6):829–840. [PubMed] [Google Scholar]
  13. Sklaroff R. B., Casper E. S., Magill G. B., Young C. W. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer Treat Rep. 1980;64(12):1247–1251. [PubMed] [Google Scholar]
  14. Thornthwaite J. T., Allen L. M. The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry. Res Commun Chem Pathol Pharmacol. 1980 Aug;29(2):393–396. [PubMed] [Google Scholar]
  15. Thornthwaite J. T., Sugarbaker E. V., Temple W. J. Preparation of tissues for DNA flow cytometric analysis. Cytometry. 1980 Nov;1(3):229–237. doi: 10.1002/cyto.990010309. [DOI] [PubMed] [Google Scholar]
  16. Weiss G. R., McGovren J. P., Schade D., Kufe D. W. Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer Res. 1982 Sep;42(9):3892–3895. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES